 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- STK-026 / Synthekine
STK-026, a detoxified IL-12 partial agonist is well-tolerated and sustains CD8+ T cell activity with repeat doses in cynomolgus macaques (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1085;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- STK-026 / Synthekine
Gradual lymphocyte activation with IL-12 partial agonist STK-026 maintains anti-tumor efficacy but escapes acute NK-mediated cytokine release and toxicities associated with WT IL-12 (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1070;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- STK-026 / Synthekine
Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1359;
Similarly, human STK-026 avoided early spikes of NK activity in cynomolgus macaques and showed reduced signs of systemic toxicities compared to hIL-12wt-Fc. These data suggest that STK-026 is a novel immunotherapy approach with the potential to maintain anti-tumor efficacy while avoiding dose limiting toxicities classically associated with IL-12 therapy.
- Novel IL-12 Partial Agonist For Cancer Immunotherapy Avoids NK-cell Mediated Toxicity (Section 24; Poster Board #5) - Mar 14, 2023 - Abstract #AACR2023AACR_3981;
These data suggest IL-12 partial agonists may represent a novel immunotherapy approach to maintain efficacy while avoiding classical toxicity associated with IL-12 therapy.1 Atkins, et al.; (1997) Clinical Cancer Research 3(3):409-172 Carson, et al. (1999) J Immunology 162 (8): 4943-4951.